Bulevirtide is an investigational, first-in-class subcutaneously injected virion entry inhibitor proposed for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.

If you have a Hayes login, click here to view the full report on the Knowledge Center.